Less than one in 10 individuals who could benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it issues its inaugural recommendations on the medications.
Considering over a billion individuals worldwide currently classified as obese, it is urging increased and just access to this class of drugs.
Per forecasts, over two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidelines affirms that obesity is a long-term condition that can be managed with holistic and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to broad availability to the injections that can assist patients in reducing substantial body mass, notes the body.
Skinny Jab Shortage
Despite the present best projected outlook, the production of such drugs could only cover about 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation calls on nations and manufacturers to expand access, by approaches including licensing agreements.
The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
The Way Obesity Drugs Function
GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and enhance satiety so individuals eat less.
Individuals commonly start to lose weight within a few weeks of commencing the weekly injections.
Research points to users may regain a significant portion a year later of stopping the medication, as their usual appetite resume.
Being carrying excess weight raises your chance for experiencing diseases, like type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity affects individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
